Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Binding and entry of animal viruses

Maja A. Sommerfelt and Mark Marsh
Chester Beatty Laboratories, The Institute of Cancer Research: Royal Cancer Hospital, London, U.K.

(Received January 4, 1988)
(Accepted July 12, 1988)

Key words: Endocytosis; Membrane fusion; Viral entry; Viral tropism; Virus binding site; Virus receptor; Virus receptor interference

Contents

Summary ................................................................................................................. 2
I. Introduction ................................................................................................... 2
II. Tropism ........................................................................................................ 3
III. The structures of viruses and their attachment sites ............................................... 4
1. Enveloped viruses ...................................................................................... 4
2. Non-enveloped viruses ................................................................................ 6
IV. Binding ......................................................................................................... 7
1. Mechanisms of virus binding ........................................................................ 7
2. Cellular binding determinants for viruses ....................................................... 8
   (a) Experimental methods for identifying virus binding sites ......................... 8
      (i) Affinity chromatography .................................................................. 8
      (ii) Antibodies against cell surface viral binding determinants ................. 8
      (iii) Chemical cross-linkers .................................................................. 9
      (iv) Transfections and cell hybrids ....................................................... 9
   (b) Viral binding components on the cell surface ............................................ 9
3. Indirect binding ......................................................................................... 11
V. Penetration .................................................................................................... 12
1. Enveloped viruses ...................................................................................... 13

Abbreviations: EBV, Epstein-Barr virus; HIV, human immunodeficiency virus; HTLV, human T-cell leukaemia virus; HA, haemagglutinin; HRV, human rhinovirus; MHC, major histocompatibility agent; VSV, vesicular stomatitis virus; SVP, subviral particle; SFV, Semliki Forest virus; NA, neuraminidase.

Correspondence: M. Marsh, Chester Beatty Laboratories, The Institute of Cancer Research: Royal Cancer Hospital, Fulham Road, London SW3 6JB, U.K.

0169-409X/89/$03.50 © 1989 Elsevier Science Publishers B.V. (Biomedical Division)
Summary

Viruses are infectious agents capable of packaging and delivering nucleic acids and proteins to specific populations of cells. To initiate infection, viruses bind to sites, or receptors, on the cell surface and transfer their genome across the limiting membrane of the cell. The mechanisms underlying these events, and viral tropism for particular host cells, are becoming increasingly well understood. Several cell surface proteins have now been identified as viral receptors, and analyses of intact virus particles and sub-viral components are revealing the structures of the binding determinants on the viruses themselves. For many viruses, the events leading to penetration and delivery involve constitutive endocytic properties of the host cell, and the low pH environment in endocytic compartments is a crucial trigger in the penetration process. The knowledge of viral tropism, binding and entry suggests strategies which may be applied to the design of targeted therapeutic agents with appropriate specificities and effective delivery mechanisms.

I. Introduction

The aim in drug targeting is to deliver efficiently a therapeutic agent, be it an antibody, gene, drug or toxin, to a specific set of cells. Virus particles are naturally designed transport vehicles whose viability is dependent on effective intercellular transport. To this end viruses have evolved mechanisms for (1) packing, transporting and delivering nucleic acid molecules and, in some cases, transcriptional enzymes to cells; (2) for avoiding host defence mechanisms; and (3) for maintaining selectivity, or tropism for specific cell populations. During the extracellular transmission phase of the life cycle, the viral genome is packaged within and protected by either a lipid and protein membrane (enveloped viruses) or a protein shell (non-enveloped viruses). On entering a host organism, the viruses must locate susceptible cells, shed the protective coat and penetrate the cell. These events are mediated by interactions between components of the viral envelope or shell and binding sites on the target cell surface. Here we discuss some of the principles that
are emerging from a better understanding of viral recognition, tropism and penetration and consider the application of these principles to the targeting of therapeutic agents.

II. Tropism

Viral tropism refers to the ability of a virus to infect specific populations of cells. Full infection leading to the release of infectious progeny virus requires the host cell to be permissive at all stages in replication. Consequently, tropism can be determined at different steps of the virus-host cell interaction.

Frequently, tropism is established at the initial binding step of the virus-host cell association and is determined by binding components on the virus [127] and the differential expression of specific cell-surface molecules that constitute the viral receptors [2,88] (cell-surface molecules are not expressed to bind viruses, rather viruses exploit these components to facilitate their entry; the term ‘receptor’ is usually reserved for cell-surface molecules involved in the uptake of macromolecules such as growth factors or hormones). Cells that lack binding sites for a specific virus, or where the binding sites are blocked, are resistant to infection by that virus. These cells may, however, support replication if the viral genome is introduced through transfection, via pseudotype viruses or alternative binding sites [44,52,131].

The role of specific cell surface binding proteins in Epstein-Barr virus (EBV) and human immunodeficiency virus (HIV) tropisms for B and T lymphocytes, respectively (the CR2 receptors for the complement component C3d and CD4 antigen, respectively) is well documented and clearly accounts for the observed tropisms of these viruses [18,23,24,87,138,56]. Similarly, the expression of as yet undetermined binding sites on cells of the nasopharynx, gut and anterior horn is believed to account for poliovirus tropism and pathogenesis [103].

The expression of receptors does not always result in productive viral infection. Cells can express binding sites for viruses that they cannot replicate. This reflects an extended receptor-host range and can be demonstrated using pseudotype viruses that contain coat components of the virus in question and the genome of a virus which the cell will replicate [108]. To release infectious viruses, cells must support all steps of the viral life cycle. Defects in replication can occur at any step in replication. For example para- and orthomyxoviruses produce a lytic infection in culture and in epithelial cells of the respiratory tract. The spike glycoproteins of these viruses are proteolytically cleaved, by cellular trypsin-like enzymes, during transport to the cell surface (see below and Fig. 1). This proteolytic cleavage is essential for the fusion activity of the progeny virions (see below). Cells that lack the appropriate enzymes bind and replicate the viruses, but produce inactive virions. The viruses fail to establish an infection and the cells appear resistant to the viruses [45,51].

Tropism can thus reflect the cell or tissue type in which viruses exert a pathogenic effect. However, virus infection does not always show pathogenic effects. The human retroviruses, T-cell leukaemia virus (HTLV) 1 and 2, are regarded as having T-cell tropism. In vivo only T-lymphocytes are transformed [131] but in culture
these viruses have an extended host range and will infect human and animal lymphoid and non-lymphoid cells [132]. It is unclear whether non-T cells are infected in vivo. The precise mechanism of HTLV-1 and 2 transformation is unclear, a viral oncogene has not been identified and they have not been found to have common integration sites. It appears that cell-specific and virally encoded trans-activating factors play a role in HTLV 1 and 2 transformation and in establishing the tissue tropism of these viruses [6].

III. The structures of viruses and their attachment sites

III.1. Enveloped viruses

The enveloped viruses, which include myxo- rhabdo-, flavi-, retro-, herpes, alpha-, bunya-, corona-, hepadna-, and arenaviruses, vary in size and morphology from the 65 nm diameter spherical virions of α-viruses to the bacilliform rhabdoviruses with dimensions of 50–95 nm diameter by 130–380 nm long. Enveloped viruses have been used extensively as models for membrane structure and biogenesis. Many of the viral proteins have been sequenced and their biosynthesis and structural properties studied in detail.

The virions contain DNA or RNA genomes complexed with one or more proteins to form a nucleocapsid particle. The nucleocapsids are assembled in the cytoplasm (or nucleoplasm for herpes virus) of the infected cells and are released by budding through a cellular membrane. On budding, they acquire a bilayer envelope which has a lipid composition similar to that of the host cell membrane [111]. Projecting out from the membrane are the viral envelope, or spike proteins (Fig. 1). These proteins are synthesised by the host cell and incorporated into the membrane from which the viruses bud. A virion contains multiple copies of each envelope protein. The 3D structure of Sindbis virus (an α-virus) indicates that each virion contains 240 copies of the spike heterodimers arranged as 80 trimeric units [27], in contrast influenza particles contain in excess of 1000 haemagglutinin (HA) molecules. The proteins contain a transmembrane polypeptide, or polypeptides, linking the spike to the membrane and are usually glycosylated. The spike proteins are multifunctional. They mediate (1) the binding of virions to host cell binding sites – virions which lack spike proteins, such as the 'bald' particles of the VSV ts 045 mutant do not bind to or infect permissive cells [130]; (2) they trigger membrane fusion properties of the virus; and (3) they assist in the process of virus budding (Refs. 82 and 111; see Fig. 1).

Although the viral proteins responsible for binding are in the main defined, the epitopes on these proteins which mediate attachment are largely uncharacterised. The 3D structures of the influenza virus HA has been determined to 3 Å resolution enabling a detailed analysis of the attachment sites [135]. HA, which mediates both attachment and fusion, is a trimer about 135 Å long and 15 – 40 Å in radius. During its biosynthesis the trimer must be correctly assembled in the endoplasmic reticulum of the infected cell in order to be transported to the Golgi apparatus and cell surface. In the course of transport the oligosaccharides are modified and, in
 Binding and Entry of Animal Viruses

## Membrane Proteins of Enveloped Viruses

| Rhabdoviruses | Alphaviruses | Orthomyxoviruses | Paramyxoviruses | Retroviruses |
|---------------|--------------|------------------|----------------|-------------|
| Vesicular Stomatitis Virus | Semliki Forest Virus | Influenza Virus | Sendai Virus | Avian Sarcoma Virus |

**Fig. 1.** Schematic representations of the subunits of the envelope proteins for five groups of enveloped animal viruses. The membrane proteins of vesicular stomatitis virus (VSV, a rhabdovirus), Semliki Forest virus (SFV, an alphavirus), influenza and Sendai virus (myxoviruses) and an avian, murine and human retrovirus are illustrated. The myxoviruses express two types of envelope protein; influenza contains a haemagglutinin/fusion protein (HA) and a binding site-destroying neuraminidase (NA), while Sendai virus contains a fusion protein (F) and a haemagglutinin/neuraminidase (HN). In contrast to the myxoviruses the rhabdo-, retro-, alpha- and flaviviruses have one type of spike protein, each subunit of which is comprised of 1–3 polypeptides. All the polypeptides are synthesised in the rough endoplasmic reticulum of infected cells and for influenza HA and VSV G at least, are assembled into trimeric spike protein units prior to transport to the Golgi apparatus and cell surface. Many are synthesised as polyproteins and are proteolytically cleaved to produce the mature proteins. The p62 subunit of SFV, for example, is cleaved to give the E2 and E3 polypeptides of the mature spike protein. Similarly, the influenza HA, Sendai F and retroviral envelope proteins are cleaved to produce the mature fusion-competent spike protein (note that the disulphide bonds which link the HA and F protein subunits in influenza and Sendai may be absent for HIV env and for at least some of the D-type retroviruses). The hydrophobic domains (indicated as filled black boxes) are believed to be involved in fusion.

Many cells, the HA subunits are proteolytically cleaved to generate the fusion competent disulphide-linked heterodimer of HA1 and HA2 (see Fig. 1 and section VI [13]). HA binds to plasma membrane glycolipids and glycoproteins containing sialic acid [43,117]. Binding occurs through a region at the top of the globular head of HA1 [135]. The site consists of a surface pocket lined by a number of amino acids which are highly conserved between different strains of the virus. Three-dimensional analysis of HA complexed with sialyllactose shows sialic acid fills this conserved pocket and confirms the role of sialic acid as the influenza receptor [128]. Variations in the sequences around the pocket modify the conformation of the site such that the virus will only bind to sialic acid residues with a specific linkage configuration. For example, certain strains of virus normally bind NeuAcα2-3Gal-containing surface molecules. When these viruses are grown in the presence of horse or guinea pig sera, containing NeuAcα2-3Gal−, mutants arise which bind NeuAcα2-6Gal+. Sequence analysis of the mutant HA genes shows a single amino acid change in the pocket region (Leu 226 → Gln or Met) is responsible for the change in binding phenotype [100].
In contrast to influenza, the 3D structure of the HIV-1 envelope protein is not resolved. Nevertheless, the attachment of this virus is relatively well understood. The gp120 fragment of the envelope glycoprotein (Fig. 1) binds with high affinity ($K_d = 4 \times 10^{-9}$ M) to human CD4 molecules [58]. The CD4-binding domain of gp120 appears to lie in a 42 amino acid (residues 397–439) region of the molecule containing a number of residues that are conserved in different strains of HIV-1. Deletion of a 12 residue peptide from within this domain decreases gp120-CD4 binding [58]. In addition, regions of the protein adjacent to the 42 amino acid domain also appear to influence binding [57].

The envelope proteins of the yellow fever and Murray valley fever flaviviruses, contain the tripeptide R-G-D [17,98]. This is a consensus sequence contained in the binding epitopes of some ligands for receptors of the integrin family, such as the fibro- and vitronectin receptors [47,102]. However, it remains to be demonstrated that R-G-D peptides are involved in flavivirus entry or whether these viruses utilize receptors of the integrin family.

III.2. Non-enveloped viruses

Non-enveloped viruses, which include the adeno-, birna-, parvo-, picorna-, papova-, and reoviruses, contain single or double stranded RNA or DNA genomes within an icosahedral capsid. The polypeptide subunits which form the capsid also mediate viral association with host cell surface and entry of the genome into the cell. The particles do not contain a lipid bilayer, though the VP4 polypeptide of picornaviruses (polio and rhinoviruses for example) and the VP2 polypeptide of SV40 and polyoma (papovaviruses) contain covalently bound myristic acid [9,115]. The amino acid sequences of many of the structural polypeptides of these viruses have been determined.

As with the enveloped viruses, non-enveloped virus capsids contain multiple attachment sites. Adenovirus binding is mediated by the fibre protein. The virion has 12 copies of this protein projecting from each of the penton bases. The fibre protein can be removed from the capsid by proteases rendering the particles incapable of binding [96]. The isolated fibres appear to retain activity and will compete with intact virus for cell surface binding sites [61].

Reovirus attachment is mediated by the σ1 polypeptide located at the vertices of the icosahedron adjacent to the λ2 (core spike) polypeptide [109]. Reoviruses have segmented double stranded RNA genomes in which recombination can occur. Mixed infections, using variants with different tropisms, give rise to progeny viruses containing reassorted genomes. The tropisms of the progeny viruses are determined by the S1 genome segment which encodes the σ1 polypeptide [127].

The 3D structures of human rhinovirus (HRV) 14 – a common cold virus – and poliovirus type 2 [46,101], have indicated putative attachment sites on the surface of picornaviruses. In HRV 14, the two capsid proteins VP1 and VP3 form a canyon or cleft on the surface of each of the icosahedral faces of the particle. The dimensions of the canyon (25 Å deep, 12–30 Å wide) are such that an antibody, in which the Fab fragment diameter is about 35 Å, would have difficulty reaching
the canyon floor – its entrance being blocked by the canyon rim. Thus residues in
the binding site would not be under selective pressure, and would enable the virus
to retain binding specificity. Variations in the amino acid sequences of the VP1
and VP3 domains that line the walls of the canyon are found in picornaviruses with
different binding specificities [101].

IV. Binding

IV.1. Mechanisms of virus binding

Binding occurs through complex interactions between a virion and the cell sur-
face (Fig. 2). In tissue culture the binding reactions are influenced by environ-
mental factors that include temperature, ionic strength, pH, composition of the
medium, presence of serum, etc. [60] (note that for viruses dependent on exposure
to acid conditions for entry, such as alphaviruses, increased binding at low pH
should not be confused with low pH-induced membrane fusion [125, see below]).

The initial virus–cell-surface interactions may be low affinity and lead to the rapid
dissociation and release of virions (viruses, such as the myxoviruses, which have

Fig. 2. Electron micrograph of SFV bound to the surface of hamster kidney cells. BHK-21 cells were
grown on glass coverslips. To bind virus, the cells were incubated with 2 µg purified SFV for 1 h at
0°C. After washing away the unbound virus the cells were fixed and processed for electron microscopy.
The figure shows virions bound to the cell surface, frequently in association with microvilli. A coated
pit also contains bound virus. Bar = 150 nm.
receptor-destroying neuraminidase activity, can be released enzymatically) or to the establishment of higher-affinity association. The increased affinity (avidity) can result from interaction with high affinity binding sites or through multiple interactions with lower affinity sites; as many viruses have multiple attachment sites a combination of the two is likely. Experiments with SFV illustrate this point. The SFV spike glycoproteins can be presented to cells in different multimeric forms, either as virions having 240 copies of the spike proteins or as artificial octameric complexes. The binding constants are $10^{-10}$-10$^{-11}$ M for virus, and $10^{-7}$ M for the octamers. BHK cells have the capacity to bind approx. $1.3 \cdot 10^6$ complexes or $5 \cdot 10^4$ virions per cell. Thus at high virus loads the number of binding interactions per SFV virion is reduced and the binding avidity decreases [25,72].

IV.2. Cellular binding determinants for viruses

Considerable effort has been spent in trying to determine the nature of the specific cell-surface determinants involved in virus binding. In recent years refined immunological techniques, molecular biology and genetics have identified at least some of these components.

IV.2(a). Experimental methods for identifying virus binding sites

(i) Affinity chromatography. Intact virions or isolated viral attachment proteins have been used to identify virus binding sites by affinity isolation. For example a 110 kDa putative glycoprotein receptor was isolated from the surface of murine L cells using spike glycoproteins of Moloney murine leukaemia virus [50] and class 1 MHC antigens were identified as potential receptors for SFV [39]. The approach requires the disruption of either the virus, or the cell plasma membrane, or both. Consequently, only monomeric interactions can occur and this approach may be limited to viruses which have a high affinity for their binding sites.

(ii) Antibodies against cell surface viral binding determinants. For viruses with a narrow host range panels of well-defined antibodies have been used to identify virus binding sites. HIV-1 is tropic for cells bearing the CD4 antigen, primarily the helper/inducer subset of T-lymphocytes. The CD4 molecule was identified as the virus binding protein using anti-T-cell monoclonal antibodies [18,56]. Antibodies against the HIV-1 binding domain of CD4, and adjacent epitopes, block infection by HIV-1 and VSV(HIV) pseudotype virus [105]. Following binding of HIV-1 to CD4 positive cells, and detergent lysis, gp120 and CD4 can be co-immunoprecipitated using antibodies against CD4 epitopes distinct from those involved in virus binding [58,63].

In other approaches monoclonal antibodies have been made against cell-surface proteins and screened for the ability to block virus binding and infection. This method has been used to identify a 90 kDa cell-surface polypeptide as a putative binding protein for HRV 15 [124]. Alternatively, anti-idiotypic antibodies, produced against anti-viral antibodies, have been used to identify the binding determinant for reovirus type 3. These anti-idiotypic antibodies should contain a mirror image of the attachment site on the viral σ1 protein. The anti-idiotypes inhibit reo-
Virus binding to cells and elicit both T and B cell immunity. They precipitate a 67 kDa glycoprotein from rodent and primate cells [10]. Both the anti-idiotype and radiolabeled virus bind to a 67 kDa plasma membrane protein on Western blots. Further characterisation of the 67 kDa antigen has suggested the β-adrenergic receptor is the viral binding protein [11].

(iii) Chemical cross-linkers. Chemical cross-linkers have been used to identify viral binding sites [3,75]. The viral attachment protein VP1 of polyoma virus can be cross-linked to cell-surface components on mouse primary kidney cells. Purified complexes injected into rabbits produce antibodies that react with VP1, stain the surface of the mouse cells and block virus binding. On Western blots the antibodies label 3 polypeptides in a plasma membrane fraction from the mouse cells. The nature of the polypeptides and their role in virus attachment remain, however, unknown [33].

(iv) Transfections and cell hybrids. Some limited information on the genes encoding viral cell-surface binding sites has been obtained by chromosome assignments using somatic cell hybrids. Human chromosome 19 encodes binding sites for poliovirus, echovirus 11, and two endogenous animal C type retroviruses (Refs. 4,49,79,84,107 and 112a). Chromosome 17 encodes binding sites for HTLV-1 and 2, and the human G chromosomes (21,22 and/or Y) encode Coxsackie B virus binding sites [53]. The identification of receptor genes has been attempted for poliovirus where total human DNA has been transfected into normally resistant mouse L cells. Transfectants expressing poliovirus binding sites have been obtained [81].

IV.2(b). Viral binding components on the cell surface

Most analyses of viral binding have been carried out in vitro, often under non-physiological conditions (e.g., low temperature). In many cases it remains unclear whether the specificities observed in culture are of functional importance for virus entry in vivo. For several viruses (e.g., HIV, EBV), however, the specific binding determinants identified in culture correlate with the disease symptoms and known tropisms of the virus.

Table 1 indicates that a range of cell-surface molecules can be involved in binding viruses that infect man and other vertebrates. The molecular nature of the binding sites, and the cellular function of these molecules, have been identified for several viruses with very specific tropisms (CD4 for HIV, CR2 for EBV). It is these proteins that are best characterised with regard to virus entry. Other viruses, such as influenza, also exhibit considerable binding specificity. Unlike the cell-specific expression of CR2 and CD4, the receptors for these viruses (N-acetylneuraminic acid; subsection III.1) are expressed on many cell-surface glycoproteins and glycolipids and enable the viruses to bind to a range of different cell types. Such broad spectrum binding determinants may be used by other viruses. Sialic acid has been implicated in binding for paramyxoviruses, picornaviruses, papovaviruses, reoviruses, and adenoviruses [2], concanavalin A binding sites for HRV-14 (see Ref. 101), and heparin sulphate proteoglycan for Herpes Simplex virus [137].

Viruses with a broad host range may bind to more than one determinant on dif-
| Virus group       | Virus                                      | Binding component                             | References |
|------------------|-------------------------------------------|----------------------------------------------|------------|
| Enveloped viruses|                                           |                                              |            |
| Retro            | human immunodeficiency virus              | CD4 (T4)                                     | 18,56      |
|                  | Moloney murine leukaemia virus            | 110 kDa glycoprotein                          | 50         |
|                  | radiation leukaemia virus                 | L3T4/T cell receptor complex                  | 92         |
| Herpes           | Epstein-Barr virus                        | CR2                                          | 23,24,87,97,120,121,138 |
|                  | Cytomegalovirus                           | β2-microglobulin/MHC                          | 34,65      |
|                  | Herpes Simplex virus                      | heparin sulphate proteoglycan                 | 137        |
| Rhabdo           | Rabies virus                              | Acetylcholine receptor                        | 59         |
|                  | Vesicular stomatitis virus                | Phosphatidyl serine                           | 106        |
| Hepadna          | Hepatitis B                               | Polyalbumin/polyalbumin receptor              | 85,122     |
| Paramyxo         | Sendai                                    | Sialic acid (glycoprotein/glycolipid)         | 71         |
| Orthomyxo        | Influenza                                 | Sialic acid (glycoprotein/glycolipid)         | 43,117     |
| Toga             | Semliki Forest virus                      | Class 1 MHC                                  | 39         |
|                  | Lactate dehydrogenase virus               | Class 2 MHC                                  | 48         |
|                  | Sindbis virus                             | 90 kDa protein/eatecholinergic receptor       | 75,123     |
| Pox              | Vaccinia                                  | Epidermal growth factor receptor             | 22         |
| Non-enveloped viruses |                                           |                                              |            |
| Picorna          | Coxsackie B                               | 49 kDa glycoprotein                           | 70         |
|                  | Rhinovirus                                | 90 kDa glycoprotein                           | 124        |
|                  | Encephalomyocarditis virus                | glycoporphin A                                | 5          |
| Reovirus         | Reovirus type 3                           | β-adrenergic receptor                         | 10,11      |
| Papova           | Polyomavirus                              | 30-40 kDa glycoprotein complex                | 33         |
| Adeno            | Adenovirus type 2                         | 78 kDa, 42 kDa, 34 kDa glycoproteins          | 42,118     |

TABLE I
IDENTIFIED AND PUTATIVE VIRUS BINDING COMPONENTS
ferent host cells. SFV, for example, binds to the major histocompatibility (MHC) antigens on human and murine lymphoblastoid cells but will also bind to and infect cells that do not express MHC antigens [39,91]. Although the identities of many virus binding sites remain to be determined, it is clear that a number of viruses may utilize the same binding sites. Competition experiments show that a number of nonenveloped viruses use four distinct binding sites on HeLa cells; group 1 is shared by the HRV types 2, -1A and -1B; group 2 by Coxsackie type A21 and HRV types 3,5,14,15,39,41,51; group 3 by all three serotypes of Poliovirus and group 4 by Coxsackie B3, other B Coxsackie viruses and Adenovirus type 2 and 5 [61]. Similarly, binding sites on cultured human cells are shared by different retroviruses (Table II). Although experimental evidence indicates that the same receptors are used by different viruses, it is unclear whether the viruses bind to the same epitopes on these molecules.

The binding reaction enables a virus to recognise, and associate with, a target cell. Does binding play any further role in entry? Endocytosis is required for penetration by certain viruses (see below). These viruses may need to bind to cell surface components which are constitutively endocytosed. Alternatively virus binding itself may induce the internalization of cell surface components that are not normally internalized, perhaps by aggregating or crosslinking these sites. Although different viruses can use the same cell surface binding sites (Table II; Ref. 61), at the present time, however, it is unclear that these molecules have any specific advantages for entry.

Enveloped virus membrane proteins may themselves bind other viruses. For example, influenza HA expressed on the surface of infected cells, can bind viruses containing sialated glycoproteins [28]. Vesicular stomatitis virus (VSV) and SFV normally infect cultured epithelial cells through the baso-lateral domain. Prior infection with influenza, in which the HA is expressed on the apical surface, enables VSV and SFV to enter through this normally non-permissive region of the plasma membrane. Similarly, BHK-21 cells which are resistant to infection by murine hepatitis virus (MHV-A59, a coronavirus) become susceptible to this virus when preinfected with influenza. This phenomenon may play a role in increasing the susceptibility of cells to secondary infections and has precedents in vivo [28,52].

In contrast, preinfection by one virus can interfere with subsequent infections by a second virus by, for example, modulating the expression of binding determinants for the second virus. Cells chronically producing retroviruses, and expressing viral envelope glycoproteins on their surface, down-regulate, shield or otherwise hide the binding site. Thereby the cells become resistant to superinfection by any retrovirus that uses the same binding sites [35,129,113].

IV.3. **Indirect binding**

In addition to direct binding, viruses may bind indirectly via natural ligands for specific cell-surface receptors. Cytomegalovirus is reported to bind to β2-microglobulin which in turn can bind to cell-surface MHC antigens [34,65] and hepatitis B virus is believed to bind to hepatocyte polymeric albumin receptors via polyal-
TABLE II
RETROVIRAL BINDING ON HUMAN CELLS
The binding determinants on human cells utilized by animal retroviruses appear to fall into eight distinct groups as determined by syncytial interference. Most retroviruses do not establish a lytic infection, instead they become chronic virus producers. Cells infected with these retroviruses down-regulate, shield or otherwise hide their cell-surface binding sites and, consequently, they become resistant to superinfection by the same virus or other viruses that utilize the same binding site. When infected cells are mixed with uninfected cells cell fusion can occur following interaction between the viral membrane proteins expressed on the infected cell and binding sites expressed on the uninfected cell. However, if cells infected with two different viruses are mixed, syncytia will only form if different binding determinants are used by each virus. If the viruses use the same binding determinants receptor interference will prevent interaction between the cells required for cell fusion [104, 112a, 113, 129, 132].

| Receptor group | Virus | Abbreviation | Retroviral type |
|----------------|-------|--------------|----------------|
| 1              | Cat endogenous | RD-114      | C-type         |
| 1              | Baboon endogenous | BaEV       | C-type         |
| 1              | Mason-Pfizer monkey virus | MPMV  | D-type         |
| 1              | Simian retrovirus 1 (SAIDS-D) | SRV-1 | D-type         |
| 1              | Simian retrovirus 2 (SAIDS-D) | SRV-2 | D-type         |
| 2              | Murine leukaemia virus amphotropic | MLV-A | C-type         |
| 3              | Murine leukaemia virus xenotropic | MLV-X | C-type         |
| 4              | Feline leukaemia virus subgroup C | FeLV-C | C-type         |
| 5              | Feline leukaemia virus subgroup B | FeLV-B | C-type         |
| 5              | Simian sarcoma associated virus | SAV | C-type         |
| 5              | Gibbon ape leukaemia virus | GALV | C-type         |
| 6              | Bovine leukaemia virus | BLV    | C-type         |
| 7              | Human T-cell leukaemia virus 1 | HTLV-1 | C-type         |
| 7              | Human T-cell leukaemia virus 2 | HTLV-2 | C-type         |
| 8              | Human immunodeficiency virus 1 HIV-1 | HIV-1 | Lenti          |
| 8              | Human immunodeficiency virus 2 HIV-2 | HIV-2 | Lenti          |

bumins [85,122]. Antiviral antibodies facilitate the infection of Fc-receptor bearing cells by flaviviruses and other viruses in culture [89,94,95], and by flaviviruses, myxoviruses, and the lentivirus subgroup of retroviruses in vivo [64,126].

V. Penetration

The binding of a virus to the cell surface initiates penetration whereby the viral nucleic acid and associated polypeptides are transferred to the cytoplasm. Enveloped virus penetration occurs by fusion between the viral and cellular membrane. For the non-enveloped viruses, however, it remains unclear how the capsid proteins interact with cellular membranes, and whether the whole capsid particle or just the nucleic acid enters the cytoplasm.
V.1. Enveloped viruses

V.1(a). Membrane fusion

Enveloped virus membrane fusion is mediated through the fusogenic spike proteins of the viral membrane (Fig. 1). These proteins are frequently the same proteins that are involved in attachment. The spike proteins are the only viral polypeptides needed for the fusion reaction, and the principal requirement for their activity is that they are anchored in a membrane [134]. The sequence and organisation of fusion proteins vary considerably between different groups of viruses; however, they can be organised into three categories.

The major group is that represented by influenza virus HA. HA is synthesised as a single polypeptide which, during transport to the cell surface, is proteolytically cleaved to form HA1 and HA2 (see subsection III.1 and Fig. 1). The cleavage results in the formation of a new terminus on HA2. This sequence is highly hydrophobic and is conserved between several different myxoviruses [134]. The hydrophobic domain is critical for the fusion activity, since HA molecules which fail to undergo proteolytic cleavage are not fusogenic. Furthermore, the introduction of charged amino acids into the hydrophobic sequence abolishes or inhibits the fusion activity [30]. The fusion proteins of paramyxoviruses and retroviruses including HIV-1, are similarly organised. In the latter case, the HIV-1 env protein has a hydrophobic domain, which is believed to be important for fusion, at the putative amino terminus of gp41. A mutant env gene encoding a protein with 4 or 6 amino acids inserted into the hydrophobic domain, will direct the expression of the precursor gp160 and the gp120 and gp41 polypeptides; however, the mature proteins are not fusogenic [57].

The second group of fusion proteins, represented by the α-viruses, contains two transmembrane polypeptides (P62 and E1 for SFV). P62 is proteolytically cleaved en route to the plasma membrane to form E2 and E3 (E3 is lost from some α-viruses and appears to be unimportant for virus entry). The α-viral proteins do not contain an N-terminal hydrophobic amino acid sequence; however, a conserved sequence of 17 uncharged amino acids is found in the ectodomain of E1 and may function in fusion [54].

The third group of fusion proteins is represented by the rhabdoviruses, such as VSV and rabies virus, which express one type of membrane protein. The spike proteins are assembled as trimers of this one polypeptide. Each of the polypeptides has one major hydrophobic domain, the transmembrane domain, which anchors the trimer into the membrane. The regions of the protein involved in fusion have not been identified.

Although the amino acid sequences of many viral fusion proteins have been determined, the mechanisms by which these proteins induce fusion is unclear. Studies with influenza and SFV have begun to determine some of the elements of the fusion reactions. With both viruses exposure to mildly acidic pH is required for fusion. The low pH induces irreversible conformational changes in the spike proteins which can be detected by changes in hydrophobicity, circular dichroism spectra, sedimentation and sensitivity to reducing agents or protease digestion [19,134].
For influenza HA, whose 3D structure is known, the acid-induced conformational changes occur when interchain salt bridges, that stabilize the HA trimer at neutral pH, are broken. The ectodomains of the trimer appear to separate and the hydrophobic N-termini of the HA2 subunits, which were previously buried within the molecule, are exposed. The hydrophobic domains are believed to interact with the target membrane and promote fusion by bringing the viral and cellular membranes into close proximity [19].

In addition to the orthomyxo- and α-viruses, exposure to acid conditions is important for the fusion of rhabdo-, flavi-, and some murine retroviruses (see Ref. 134). Other enveloped viruses, such as the paramyxovirus Sendai and HIV-1, do not require exposure to acid pH for fusion [62,114]. The fusion efficiency of Sendai virus is the same at neutral and mildly acid pH, and is slightly enhanced in mildly alkaline conditions. Although the organisation of the fusion proteins of Sendai and HIV-1 is similar to that of influenza HA (Fig. 1), it is not known if the proteins are multimeric, or whether the hydrophobic fusion peptides are only exposed during the fusion reaction.

In general viral fusion does not require specific lipids and can occur with membranes containing a normal complement of phospholipids, though cholesterol must be present in the target membrane for SFV fusion (see Ref. 134). SFV and influenza-induced fusion does not appear to require binding components in the target membrane, and under appropriate conditions, the viruses will fuse with liposomes devoid of protein (see Ref. 134).

V.1(b). Endocytosis

The nature of the fusion trigger requires that pH-dependent viruses encounter an acidic environment. Under normal circumstances the virions do not fuse at the cell surface and penetration occurs only after endocytosis of intact virions into acidic intracellular organelles.

The endocytic uptake of SFV has been studied in detail [40]. Following binding, the virions are internalized intact and presumably in association with the cell-surface binding components (Fig. 3). Internalization occurs through clathrin-coated pits, in coated vesicles, in a manner similar to the receptor-mediated endocytosis of physiological ligands such as low-density lipoprotein and transferrin [31]. Endocytosis through coated vesicles has a considerable capacity. In BHK-21 cells, for example, up to 3000 SFV particles can be internalized from the cell surface each minute [72]. The virions are internalized, together with other receptor-bound ligands, by the cells' constitutive endocytic activity, and uptake is not induced by the virus [72]. Other viruses, including influenza, Sendai and VSV are also internalized in coated vesicles [15,16,76,77], although with varying kinetics [76,77]. The limiting factor appears to be the size of the virus particles. SFV (65 nm diameter particles) can be contained within most endocytic coated vesicles (average diameter 100 nm) and is internalized rapidly \( (t_{1/2}=5-10 \text{ min}) \) [72]), while larger viruses, such as influenza (100 nm diameter) and VSV (150 nm long) are internalized more slowly \( (t_{1/2}=10-15 \text{ and } 30 \text{ min}, \text{ respectively}) \) [76,77]).

Clathrin-coated vesicles mediate the bulk of constitutive endocytosis in many cell
types and are clearly involved in the uptake of many viruses; however, other endocytic processes may internalize viruses in certain circumstances. Influenza and Sendai virions often appear wrapped in non-coated membrane [36,76], suggesting that a process similar to the phagocytic uptake of large opsonised particles may be operating. Similarly larger virions such as EBV (250 nm diameter) are reported to enter B lymphocytes in non-coated vesicles [88].

Coated vesicles rapidly lose their clathrin coat and fuse with organelles of the endosome compartment. The endosomes are the receiving station for membrane, receptors and components of the medium internalized by coated vesicles [41]. The major function of endosomes is to sort and recycle internalized membrane components to the plasma membrane and different sites within the cell [31]. The mechanisms by which this sorting is achieved involves acidification of the organelles by membrane-associated proton-translocating ATPases [78,80]. The endosome compartment appears to be the first stage on the endocytic pathway in which acidification occurs [26] and the pH decreases to approx. 5.0 by the time ligands reach the lysosomes, the terminal compartment of the pathway.

SFV, Sindbis and influenza have been shown by a combination of kinetic, morphological, biochemical and cell fractionation experiments to enter intact into the endosome compartment [73,99,119,139]. For these pH-dependent viruses, the acid conditions in endosomes trigger the reactions which lead to fusion of the viral and endosomal membranes. Internalized viruses have been shown to be infectious [38]
and fusion of SFV with endosome membranes has been visualized [37]. Following internalization the time-course of penetration varies according to the pH dependence of the fusion reaction. Viruses requiring a relatively high pH (wild type SFV, pH 6.1) fuse quickly \( (t_{1/2} = 15 \text{ min}, \text{ including the time for endocytosis}) \), while those that require more acidic conditions (SFV mutant fus-1, pH 5.3) fuse later \( (t_{1/2} = 45 \text{ min}) \). Fusion for both viruses occurs in the endosomes prior to delivery to the lysosomes [54,55,73]. Viral components are eventually delivered to the lysosomes where degradation occurs. Following the completion of their functions in entry the viral spike proteins, and viruses that fail to undergo fusion, are delivered to the lysosomes and degraded [73].

The dependence of viral infection on exposure to acid conditions, and the consequent requirement for endocytosis, presents a point at which penetration can be blocked. Acidotropic weak bases, such as ammonium chloride, chloroquine, amantadine or methylamine accumulate in endosomes and other acid compartments causing an increase in the intravesicular pH [78,90]. Similarly, carboxylic ionophores such as monensin and nigericin will neutralise acidic organelles by exchanging \( \text{H}^+ \) for \( \text{Na}^+ \) or \( \text{K}^+ \). Infection by a range of pH-dependent viruses, including influenza, SFV, VSV and West Nile virus, is blocked when cells are incubated with these reagents [32,38,74,76,77,99,139]. Although weak bases and carboxylic ionophores can affect a number of steps in the replication cycle, experiments with SFV and influenza show that binding, endocytosis and intracellular transport to endosomes are not inhibited by \( \text{NH}_4\text{Cl} \) or monensin. In the presence of the agents the spike proteins, however, fail to undergo the acid-induced conformational changes required for fusion. As a consequence the viruses do not fuse with the endosome membrane, the viral RNA is not released to the cytoplasm and replication does not proceed (Fig. 3). The efficacy of the reagents is related to the pH at which the viral fusion proteins undergo the conformational change, i.e., the higher the pH required for fusion the higher the concentration of drug required to block infection.

The effect of acidotropic agents can be by-passed by briefly incubating cells, with bound virus, in low pH medium and, thereby, inducing fusion at the cell surface [38,74]. Thus the reagents do not act directly on the virus itself, but indirectly through an effect on the pH of the acid compartments in which fusion usually occurs. Weak bases and carboxylic ionophores do not affect the fusion of pH-independent viruses [62,114].

V.2. Non-enveloped viruses

Compared to the enveloped viruses the penetration mechanisms for non-enveloped viruses is less well understood. The endocytic uptake of adeno-, reo-, polya- and picornaviruses has been observed both biochemically and morphologically [16,33,110] and it is now clear that some of these viruses require endocytosis for penetration.

For poliovirus type 1 entry is blocked by acidotropic amines, carboxylic ionophores and other reagents (2-deoxy-d-glucose, \( \text{NaN}_3 \)) which inhibit endocytosis or
endosome acidification. This inhibition can be by-passed if the cells with bound
virus are incubated briefly at low pH [67]. Low pH treatment induces changes in
isolated virions (loss of VP4 and an increase in hydrophobicity) similar to changes
in the virions observed during entry into cells. The changes are not found during
the uptake of virions into cells treated with the inhibitors, suggesting that exposure
to low pH also triggers critical conformational changes in these non-enveloped vi-
ruses [67,68]. However, low pH alone is not sufficient for entry. A pH-gradient
across the membrane is required and disruption of this gradient – by, for example,
acetic acid-induced acidification of the cytoplasm – inhibits poliovirus infection [68].

Although acidotropic reagents inhibit the entry of poliovirus, HRV type 2 and
foot and mouth disease virus [6,69], they do not block the entry of all picornavi-
ruses. Murine EMC virus infection is enhanced by monensin, suggesting that entry
requires neutral or mildly alkaline conditions [69].

It has been suggested [101] that occupation of the binding canyon on poliovirus
could facilitate disruption of the pentamer-pentamer contacts in the capsid and
provide a port by which VP4 and RNA can exit the virion, possibly accompanied
by a change in the isoelectric point of the virus. Thus binding may facilitate pen-
etration by unlocking the capsid. Experiments on the pH dependency of the con-
formational changes observed in poliovirus type 1 support this idea. The changes
are influenced by both temperature and cell association of the virus. For free virus
the conformational changes are half maximal at pH 5.0, but following binding they
are half maximal at pH 6.1–6.5 [68].

A low pH-dependent step has also been implicated in adenovirus penetration.
Morphological experiments show that bound virions are internalized in coated ves-
icles and delivered to endosomes [16,93]. Subsequently, virions can be observed
in the cytoplasm, suggesting that the entire capsid is translocated across the mem-
brane. Cells treated with the weak bases chloroquine and methylamine are pro-
tected from infection, and the virions do not undergo acid-induced changes in the
hydrophobicity of the penton base, hexon and fibre proteins [93].

With reovirus a variation on the theme of pH-induced changes occurs. Virions
are internalized by receptor-mediated endocytosis, through coated pits and coated vesicles and are delivered to endosomes and lysosomes [116,110]. Within intra-
cellular vesicles, the viral outer capsids are digested to produce partially uncoated
subviral particles (SVPs). The growth of reovirus types 1 and 3 in mouse L cells
is inhibited by ammonium chloride. The effect of NH₄Cl occurs early in infection,
within 1 h of virus addition. It does not influence the binding, endocytosis or in-
tracellular routing of the virus, but does inhibit digestion of the outer capsid pro-
teins. If virions are digested with protease prior to infection, intermediate particles
are produced that are infectious and insensitive to NH₄Cl [116]. It is unclear
whether the low pH-dependent protease is viral or cellular; however, it is clear
that digestion is essential for the infectious cycle.

The fact that low pH and proteolytic digestion are important for entry raises the
question of how reoviruses initially enter their host. As entry appears to occur
through specialized M cells of the small intestine, the viruses must pass through
the acidic hydrolytic environment of the stomach and the alkaline small intestine
to reach its target site. Whether these environments influence the entry process in any way, or how the viruses survive the adverse conditions, is unclear.

V.3. The role of endocytosis in infection

Low pH is necessary for the penetration and entry of many viruses. Exposure to low pH can only occur within acidic vesicles following endocytosis of the virions. With the pH-independent viruses, however, penetration can occur in acid, neutral or alkaline conditions [134] and can occur at the cell surface or from intracellular vesicles. While it is clear with Sendai virus or HIV-1, for example, that fusion can occur at the cell surface [36,114], it is unclear whether this fusion results in productive infection. Experiments with SFV and HIV-1 (Ref. 93a; see also Marsh, M., unpublished results) suggest that endocytosis is important for the entry of both pH-dependent and pH-independent viruses. The reason why the pH-independent viruses should require endocytosis is unclear, but the possibility exists that for replication to occur the fusion reaction must deliver the viral genome to an appropriate site in the cytoplasm and endocytosis is the means by which this delivery is achieved.

VI. Prospects for drug development

The fundamental requirements of drug targeting are in many respects the same as those of virus transmission. Reagents must be packaged in forms suitable to ensure that (1) they are not degraded in transit and (2) any toxic effects of the cargo are minimised until delivery is complete. The carriers must have specificity to ensure their arrival at a designated target and appropriate mechanisms to release then their cargo. By extending the characteristics of viruses that are essential for entry to the design of drug delivery systems it may be possible to develop carriers as effective as the viruses themselves. In several applications viruses have already been successfully exploited as delivery vehicles.

(1) Viruses as genetic vectors. Modified vaccinia virus incorporating genes encoding the spike proteins of enveloped viruses such as influenza and HIV-1 have been used as vaccine reagents [140]. Retroviruses are used routinely as genetic vectors for transfection in vitro [8], and are currently being adapted for use in vivo [1]. In the future retrovirus vectors may well be used in gene replacement therapies to treat a range of genetic diseases including disorders in haemoglobin (sickle cell anaemia, β-thalassaemia), severe combined immunodeficiencies and adenosine deaminase deficiency [1,20]. In addition retroviruses, with well-defined tropisms, may be modified to function as cytopathic agents by incorporating genes encoding cytotoxins such as the A chains of ricin or diphtheria toxin.

(2) Viruses as carrier vehicles. By replacing the nucleocapsid, within a virus particle, with an alternative cargo of nucleic acid, protein or drugs, it has been possible in culture to deliver these reagents to target cells. In addition, enveloped viruses can be used to deliver integral membrane proteins, such as receptors, to specific membrane systems. The most extensively used of these pseudo-viral par-
ticles is the Sendai virus. The virus particles can be solubilized in Triton X-100, the capsids removed and the membrane reassembled by removing the detergent. When this reconstitution is performed in the presence of exogenous proteins or nucleic acids, particles are formed which contain the protein or nucleic acid in the lumen of the vesicle. Particles can also be reconstituted in which specific membrane proteins are assembled into the virosome membrane. The reconstituted envelopes have the sialic acid binding and fusion properties of intact Sendai virus and can be used to deliver their soluble or membrane-bound load to target cells [29,103]. The specificity of these carriers can be modified by selectively destroying the sialic acid binding (haemagglutinin) activity and covalently linking specific antibodies or ligands [29,103].

Although these carriers have been used with some success to deliver receptors, DNA, RNA and antibodies in tissue culture systems, their full potential is unclear. In general reconstituted vesicles are inefficient in fusion compared to the intact virus. Much of the lost activity can be attributed to failures to efficiently reconstitute the fusion activity of detergent solubilized fusion proteins. Recent experiments with VSV, however, indicate that with appropriate reconstitution vesicles can be formed for which fusion is as efficient as that of intact virus [83]. As yet similar strategies based on non-enveloped viruses have not been used, but as the 3D structures of the viruses emerge and the interactions of the capsid sub-units are understood, development possibilities may emerge.

Further applications for virus-based carriers can be envisaged whereby the tropism or specificity of a virus is changed so as to target the virus to specific cells. Pseudotype viruses, in which the genome of one virus is coated with the shell or envelope of a different virus, have been used in culture systems to change the specificity and host range of a virus [14,21,131], and to provide viruses capable of a single round of infection. Alternatively, by understanding the structural parameters of the binding reactions, the binding epitopes on viral attachment proteins could be modified to change the binding specificity of a virus, to alter its tropism or to target carriers to specific cell populations. Such altered proteins could be utilized with the reconstituted carriers described above to target virosomes to specific cells. The requirement for low pH in the entry of some viruses might be exploited to produce carriers aimed at endocytically active cells, or at different compartments of the cell.

In order to adapt the structural features of viruses into effective drug delivery systems it is clear that many key problems remain to be solved. For example:

(1) what are the molecular mechanisms of viral tropism?
(2) what are the molecular identities and cellular functions of virus receptors?
(3) do cell-surface molecules have specific properties that allow them to function as receptors for viruses?
(4) what is the distribution of viral receptors on different cell populations?
(5) what are the molecular mechanisms underlying viral fusion and penetration reactions?
(6) how can isolated viral proteins be reconstituted into fully functional forms?
Analysis of the interactions of viruses with epithelial cells will also have important implications for drug delivery. For example, understanding the mechanism by which reovirus and poliovirus penetrate the epithelium of the gut may suggest mechanisms by which orally administered therapeutic agents might be delivered across this barrier [136].

The possibilities are considerable. However, it is clear that any successful exploitation of viruses in drug delivery systems must be based on a sound understanding of the interactions between a cell and a virion, and of the factors that underlie viral tropism.

Note added in proof (received June 28, 1989)

Since submission of this article, putative receptor proteins have been identified for several viruses. Using the transfection methods outlined in this review, a murine gene encoding a multi-spanning membrane protein has been shown to confer susceptibility to ecotropic murine leukaemia virus (Albritton, L.M., Tseng, L., Scadden, D. and Cunningham, J.M. (1989) A putative murine retrovirus receptor gene encodes a multiple membrane spanning protein and confers susceptibility to virus infection, Cell 57, 659–666). Similarly, ICAM-1 and a second, previously unidentified, member of the immunoglobulin gene superfamily have been proposed as receptors for human rhinovirus and poliovirus, respectively (Greve, J.M., Davis, G., Meyer, A.M., Forte, C.P., Yost, S.C., Marlor, C.W., Karmarck, M.E. and McClelland, A. (1989) The major human rhinovirus receptor is ICAM-1, Cell 56, 839–847; Staunton, D.E., Merluzzi, V.J., Rothlein, R., Barton, R., Marlin, S.D. and Springer, T.A. (1989) A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinovirus; Cell 56, 849–853; Mendelsohn, C.L., Wimmer, E. and Racaniello, V.R. (1989) Cellular receptor for poliovirus: molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulin superfamily, Cell 56, 855–865).

Acknowledgements

We thank our colleagues – Annegret Pelchen, Mark Exley, Victoria Anne Lewis, Jane McKeating, Eddie Wawrzynczak and Robin Weiss – for helpful discussions and for reading the manuscript. The authors are supported by grants to The Institute of Cancer Research: Royal Cancer Hospital from the Cancer Research Campaign and the Medical Research Council.

References

1 Blease, R.M., Kohn, D.B. and Moen, R.C. (1987) The treatment of adenosine deaminase deficiency, Immunol. Today 8, 296–297.
2 Burness, T.H. (1981) Glycophorin and sialylated components as receptors for viruses. In: K. Lonberg-Holm and L. Philipson (Eds.), Virus Receptors, Part 2. Animal Viruses. Receptors and Recognition Series B, Vol. 8, Chapman and Hall, London, pp. 63–84.
3 Boulanger, P. and Philipson, L. (1981) Membrane components interacting with non-enveloped an-
BINDING AND ENTRY OF ANIMAL VIRUSES

- References to various research papers and studies on the binding and entry mechanisms of animal viruses, including receptor interactions and their implications.

1. Brown, S., Otte, H.K., Gazdar, A.F. and Minna, J.D. (1979) Requirement for human chromosomes 1, 6 and possibly 3 for infections of human × hamster hybrid cells with baboon M7 type C virus, Cell 18, 135-143.

2. Burrows, A.T.H. and Fardoe, I.U. (1983) A sialoglycopeptide from human erythrocytes with receptor-like properties for encephalomyocarditis viruses, J. Gen. Virol. 64, 1137-1148.

3. Carillo, E.C., Giachetti, C. and Campos, R.H. (1984) Effect of lysosomotropic agents on the foot and mouth disease virus replication, Virology 135, 542-545.

4. Chen, P., McLaughlin, J. and Golde, D.W. (1984) Long terminal repeats of human T-cell leukemia virus II genome determine target cell specificity, Nature 309, 276-279.

5. Copito, C.L., Roberts, B.E. and Mulligan, R.C. (1984) Construction and applications of a highly transmissible retrovirus shuttle vector, Cell 37, 1053-1062.

6. Chow, M., Newman, J.F.E., Filman, D., Hogle, J.M., Rowlands, D.J. and Brown, F. (1987) Myristilation of picornavirus capsid protein VP4 and its structural significance, Nature 327, 482-486.

7. Colman, P.M., Varghese, J.N. and Laver, W.G. (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase, Nature 303, 41-44.

8. Copeland, C.S., Doms, R.W., Bolzau, E.M., Webster, R.G. and Helenius, A. (1986) Assembly of influenza hemagglutinin trimers and its role in intracellular transport, J. Cell Biol. 103, 1179-1192.

9. Dahlberg, D. E. (1974) Quantitative electron microscopic analysis of the penetration of VSV into L cells, Virology 58, 256-262.

10. Dalgleish, A.G., Beverley, P.C.L., Clapham, P.R., Crawford, D.H., Greaves, M.F. and Weiss, R.A. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature 312, 763-767.

11. Doms, R.W. and Helenius, A. (1986) Quaternary structure of the influenza virus hemagglutinin after acetyl treatment. J. Virol. 60, 833-839.

12. Doggett, R.A., Papayannopoulou, T. and Mulligan, R.C. (1988) Lineage specific expression of a human β-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells, Nature 331, 35-41.

13. Easton, J.M. and Hiatt, C.W. (1965) Possible incorporation of SV40 genome within capsid proteins of Adenovirus 4. Proc. Natl. Acad. Sci. USA 54, 1100-1104.

14. Epstein, D.A., Marsh, Y.V., Schreiber, A.B., Newman, S.R., Todaro, G.J. and Nestor, J.J., Jr. (1985) Epidermal growth factor occupancy inhibits vaccinia virus infection, Nature 318, 663-665.

15. Fingeroth, J.D., Weiss, J.J., Tedder, T.F., Strominger, J.L., Biro, P.A. and Fearon, D.T. (1984) Epstein-Barr virus receptor of human B-lymphocytes is the C3d receptor CR2, Proc. Natl. Acad. Sci. USA 81, 4510-4514.

16. Fries, E. and Helenius, A. (1979) Binding of Semliki Forest virus and its spike glycoproteins to cells, Eur. J. Biochem. 97, 213-220.

17. Fuchs, R., Ellinger, A., Pavelka, M., Peterlik, M. and Mellman, I. (1987) Endocytic coated vesicles do not exhibit ATP-dependent acidification in vitro, J. Cell Biol. 105, 91a.

18. Fuller, S.D. (1987) The T=4 envelope of Sindbis virus is organized by interactions with a comple-
mentary T=3 capsid, Cell 48, 923–934.

28 Fuller, S.D., Von Bonzdorff, C.-H. and Simons, K. (1985) Cell surface influenza haemagglutinin can mediate infection by other animal viruses, EMBO J. 4, 2475–2485.

29 Gitman, A.G., Kahane, I. and Loyter, A. (1985) Use of virus-attached antibodies or insulin molecules to mediate fusion between Sendai envelopes and neuraminidase-treated cells, Biochemistry 24, 2762–2768.

30 Gething, M.-J., Doms, B., York, D. and White, J. (1986) Studies on the mechanism of membrane fusion: site specific mutagenesis of the hemagglutinin of influenza virus, J. Cell Biol. 102, 11–23.

31 Goldstein, J.L., Brown, M.S., Anderson, R.G.W., Russell, D.W. and Schneider, W.J. (1985) Receptor mediated endocytosis: Concepts emerging from the LDL receptor system, Annu. Rev. Cell Biol. 1, 1–39.

32 Gollins, S.W. and Porterfield, J.S. (1986) The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effect of pH and ammonium chloride, J. Gen. Virol. 67, 1941–1950.

33 Griffiths, G.R. and Consigli, R.A. (1986) Cross linking of a polyoma virus attachment protein to its mouse kidney cell receptor, J. Virol. 58, 773–781.

34 Grundy, J.E., McKeating, J.A., Ward, P.J., Sanderson, A.R. and Griffiths, P.D. (1987) B2-microglobulin enhances the infectivity of cytomegalovirus and when bound to the virus enables class 1 HLA molecules to be used as a virus receptor, J. Gen. Virol. 68, 793–803.

35 Hartley, J.W., Rowe, W.P. and Huebner, R.J. (1980) Host range restrictions of murine leukaemia viruses in mouse embryo cultures, J. Virol. 5, 221–225.

36 Hayward, A.M. (1987) Fusion of virus membranes with phospholipid vesicles at neutral pH. In: J. Wilschut and D. Hoekstra (Eds.), Cellular membrane fusion, Marcel Dekker, New York, in press.

37 Helenius, A. (1984) Semliki Forest penetration from endosomes: a morphological study, Biol. Cell 51, 181–186.

38 Helenius, A., Marsh, M. and White, J. (1982) Inhibition of Semliki Forest virus penetration by lysosomotropic weak bases, J. Gen. Virol. 58, 47–61.

39 Helenius, A., Morein, B., Fries, E., Simons, K., Robinson, P., Schirrmacher, V., Terhorst, C. and Strominger, J.L. (1978) Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus, Proc. Natl. Acad. Sci. USA 75, 3846–3850.

40 Helenius, A., Kartenbeck, J., Simons, K. and Fries, E. (1980) On the entry of Semliki Forest virus into BHK-21 cells, J. Cell Biol. 84, 404–420.

41 Helenius, A., Mellman, I., Wall, D. and Hubbard, A. (1983) Endosomes, TIBS 8, 245–250.

42 Hennache, B. and Boulanger, P. (1977) Biochemical study of KB-cell receptor for adenovirus, Biochem. J. 166, 237–247.

43 Herrler, G., Rott, R. and Klenk, H.-D. (1985) Neuraminic acid is involved in the binding of influenza C virus to erythrocytes, Virology 141, 144–147.

44 Holland, J.J., McClaren, L.C. and Syvertson, J.T. (1959) Mammalian cell virus relationship; (IV) infection of naturally susceptible cells with enterovirus ribonucleic acid, J. Exp. Med. 110, 65–80.

45 Holmes, K.V. (1985) Replication of Coronavirus. In: B.N. Fields (Ed.), Virology, Raven Press, New York, pp. 1331–1344.

46 Hogle, J.M., Chow, M. and Filman, D.J. (1985) Three-dimensional structure of poliovirus at 2.9 Å resolution, Science 229, 1358–1365.

47 Hynes, R.O. (1987) Integrins: a family of cell surface receptors, Cell 48, 549–554.

48 lnada, T. and Mims, C.A. (1984) Mouse la antigens are receptors for lactate dehydrogenase virus, Nature 309, 59–61.

49 Kaneda, Y., Hayes, H., Uchida, T., Yoshida, M.C. and Okada, Y. (1987) Regional assignment of five genes on human chromosome 19, Chromosoma 95, 8–12.

50 Johnson, A.P. and Rosner, M.R. (1986) Characterisation of murine-specific leukaemia virus receptor from L cells, J. Virol. 58, 900–908.

51 Kauffman, R.S. and Fields, B.N. (1985) Pathogenesis of viral infection. In: B.N. Fields (Ed.), Virology, Raven Press, New York, pp. 153–168.

52 Khelifa, R. and Menezes, J. (1983) Sendai virus envelopes can mediate Epstein-Barr virus binding to and penetration into Epstein-Barr virus receptor-negative cells, J. Virol. 46, 325–332.
Khesin, Y.E., Amtanchenkova, A.M. and Sovjetova, G.P. (1974) Group G chromosomes and the susceptibility of cells of human origin to Coxsackie viruses, J. Gen. Virol. 23, 17-22.

Kielian, M. and Helenius, A. (1985) pH-induced alterations in the fusogenic spike protein of Semliki forest virus, J. Cell Biol. 101, 2284-2291.

Kielian, M. C., Marsh, M. and Helenius, A. (1986) Kinetics of endosome acidification detected by mutant and wild-type Semliki forest virus, EMBO J. 5, 3103-3109.

Klatzmann, D., Champagne, E., Chamaret, S., Gueret, J., Guetard, D., Hercend, T., Gluckman, J.-C. and Montagnier, L. (1984) T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312, 767-768.

Kowalski, M., Pozz, J., Basiripour, L., Dorfman, T., Goh, W.C., Te'llwilliger, E., Dayton, A., Rosen, C., Haseltune, W. and Sodroski, J. (1987) Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1, Science 237, 1351-1355.

Kielian, M. (1985) pH-induced alterations in the fusogenic spike protein of Semliki forest virus, J. Cell Biol. 101, 2284-2291.

Lasky, I.A., Nakamura, G., Smith, D.H., Fennie, C., Shimasaki, C., Patzer, E., Berman, P., Gregory, T. and Capon, D.J. (1987) Delineation of a region of the human immunodeficiency virus type 1 gpl20 glycoprotein critical for interaction with the CD4 receptor, Cell 50, 975-985.

Lentz, T.L., Burragc, T.G., Smith, A.L., Crick, J. and Tignor, G.H. (1982) Is the acetylcholine receptor a rabies virus receptor? Science 215, 182-184.

Lonberg-Holm, K. (1981) Attachment of animal viruses to cells: an introduction. In: K. Lonberg-Holm and L. Philipson (Eds.), Virus Receptors, Part 2, Animal Viruses. Receptors and Recognition Series B. Vol. 8. Chapman and Hall, London, pp. 1-20.

Lonberg-Holm, K., Crowell, R.L. and Philipson, L. (1976) Unrelated animal viruses share receptors, Nature 258, 679-681.

Loyter, A., Tomasi, M., Gitman, A.G., Etinger, L. and Nussbaum, O. (1984) The use of specific antibodies between Sendai virus envelopes and living cells, CIBA Foundation Symposium 103, 163-175.

McClure, M.O., Marsh, M. and Weiss, R.A. (1987) Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism, EMBO J. 7, 513-518.

McDougal, J.S., Kennedy, M.S., Sligh, J.M., Cort, S.P., Mawle, A. and Nicholson, J.K.A. (1986) Binding of HIV-3/LAV to T4+ T-cells by a complex of the 110k viral protein and the T4 molecule, Science 231, 382-385.

McGuire, T.C., Adams, S., Johnson, G.C., Klevjer-Anderson, P., Barbee, D.D. and Gorham, J.R. (1986) Acute arthritis in caprine arthritis-encephalitis virus challenge exposure of vaccinated or persistently infected goats, Am. J. Vet. Res. 47, 537-540.

McKeating, J.A., Griffiths, P.D. and Grundy, J.E. (1987) Cytomegalovirus in urine specimens has host β₂-microglobulin bound to the viral envelope: A mechanism of evading the host immune response? J. Gen. Virol. 68, 785-792.

Maddon, P.J., Dalglish, A.G., McDougal, J.S., Clapham, P.R., Weiss, R.A. and Axel, R. (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immunosystem and the brain, Cell 47, 333-348.

Madsbush, I.H., Olsnes, S. and Sandvig, K. (1984) Mechanisms of entry into the cytosol of poliovirus type 1: requirements for low pH, J. Cell Biol. 98, 1194-1200.

Madsbush, I.H., Olsnes, S. and Sandvig, K. (1984) Requirements for entry of poliovirus RNA into cells at low pH, EMBO J. 3, 145-150.

Madsbush, I.H., Olsnes, S. and Sandvig, K. (1984) Different pH requirements for entry of the two picornaviruses, human rhinovirus 2 and murine encephalomyocarditis virus, Virology 139, 346-357.

Mapoles, J.E., Krah, D.L. and Crowell, R.L. (1985) Purification of a HeLa cell receptor protein for group B coxsackie viruses, J. Virol. 55, 560-566.

Markwell, M.A.K., Fredman, P. and Svennerholm, L. (1984) Receptor ganglioside content of three hosts for Sendai virus, Biochim. Biophys. Acta 775, 7-16.

Marsh, M. and Helenius, A. (1980) Adsorptive endocytosis of Semliki Forest virus, J. Mol. Biol. 142, 439-454.

Marsh, M., Bolzau, E.-M. and Helenius, A. (1983) Penetration of Semliki Forest virus acidic prelysosomal vacuoles, Cell 32, 931-940.

Marsh, M., Wellstead, J., Kern, H., Harms, E. and Helenius, A. (1982) Monensin inhibits Semliki
Forest virus penetration into culture cells, Proc. Natl. Acad. Sci. USA 79, 5297-5301.
75 Massen, J.A. and Terhorst, C. (1981) Identification of a cell-surface protein involved in the binding site of Sindbis virus on human lymphoblastic cell lines using a heterobifunctional cross-linker, Eur. J. Biochem. 115, 153-158.
76 Matlin, K.S., Reggio, H., Helenius, A. and Simons, K. (1982) Infectious entry pathway of influenza virus in a canine kidney cell line, J. Cell Biol. 91, 601-613.
77 Matlin, K.S., Reggio, H., Helenius, A. and Simons, K. (1982) Pathway of vesicular stomatitis virus entry leading to infection, J. Mol. Biol. 156, 609-631.
78 Maxfield, F.R. (1982) Weak bases and ionophores rapidly and reversibly raise the pH in endocytic vesicles in cultured mouse fibroblasts, J. Cell Biol. 95, 676-681.
79 Medrano, L. and Green, H. (1973) Picornavirus receptors and picornavirus multiplication in human-mouse hybrid cell lines, Virology 54, 515-524.
80 Mellman, I., Fuchs, R. and Helenius, A. (1986) Acidification of the endocytic and exocytic pathways, Annu. Rev. Biochem. 55, 663-700.
81 Mendelsohn, C., Johnson, B., Lionetti, K.A., Nobis, P., Wimmer, E. and Racaniello, V.R. (1986) Transformation of a human poliovirus receptor gene into mouse cells. Proc. Natl. Acad. Sci. USA 83, 7845-7849.
82 Metsikko, K. and Simons, K. (1986) The budding mechanism of spikeless vesicular stomatitis virus particles, EMBO J. 5, 1913-1920.
83 Metsikko, K., Van Meer, G. and Simons, K. (1986) Reconstitution of the fusogenic activity of vesicular stomatitis virus, EMBO J. 5, 3429-3435.
84 Miller, D.A., Miller, O.J., Dev, V.G., Hashm, S. and Tantravali, R. (1974) Human chromosome 19 carries a Poliovirus receptor gene, Cell 1, 167-173.
85 Mondelli, M. and Eddleston, A.L.W.F. (1984) Mechanisms of liver cell injury in acute and chronic hepatitis B. In: M.A. Gerber (Ed.), Seminars in liver disease. 4. Thieme Stratton, New York, pp. 47-58.
86 Morishima, T., McClintock, P.R., Billups, L.C. and Notkins, A.L. (1982) Expression and modulation of virus receptors on lymphoid and myeloid cells: relationship to infectivity, Virology 116, 605-618.
87 Nemerow, G.R., Wolfert, R., McNaughton, M.E. and Cooper, N.R. (1985) Identification and characterisation of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor, J. Virol. 55, 347-351.
88 Nemerow, G.R. and Cooper, N.R. (1984) Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process, Virology 132, 186-198.
89 Nussbaum, O., Zakai, N. and Loyter, A. (1984) Membrane bound antiviral antibodies as receptors for Sendai virions in receptor depleted erythrocytes, Virology 138, 185-197.
90 Ohkuma, S. and Poole, B. (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents, Proc. Natl. Acad. Sci. USA 75, 3327-3331.
91 Oldstone, M.B.A., Tishon, A., Dutko, F.J., Kennedy, S.I.T., Holland, J.J. and Lamoert, P.W. (1980) Does the major histocompatibility complex serve as a specific receptor for Semliki Forest virus, J. Virol. 34, 256-265.
92 O'Neill, H.C., McGrath, M.S., Allison, J.P. and Weissman, I.L. (1987) A subset of T cell receptors associated with L3T4 molecules mediates C6VL leukaemia cell binding of its cognate retrovirus, Cell 49, 143-151.
93 Pastan, I., Seth, P., Fitzgerald, D. and Willingham, M. (1986) Adenovirus entry into cells: new observations on an old problem. In: A.L. Notkins and M.B.A. Oldstone (Eds.), Concepts in viral pathogenesis II, Springer-Verlag, New York, pp. 141-146.
93a Pauza, C.D. and Price, T.M. (1988) Human immunodeficiency virus infection of T-cells and monocytes proceeds via receptor-mediated endocytosis, J. Cell Biology 107, 959-968.
94 Peiris, J.S.M. and Porterfield, J.S. (1979) Antibody mediated enhancement of Flavivirus replication in macrophage-like cell lines, Nature 282, 509-511.
95 Peiris, J.S.M., Gorden, S., Unkeless, J.C. and Porterfield, J.S. (1981) Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. Nature 289, 189-191.
96 Prage, L., Petterson, U., Höglund, S., Lonberg-Holm, K. and Philipson, L. (1970) Structural pro-
BINDING AND ENTRY OF ANIMAL VIRUSES

teties of adenoviruses. IV sequential degradation of the adenovirus type 2 virion, Virology 42, 341-388.

97 Rettig, P.S., Spjut, R.C., Townsend, P.L., Stanford, S.A., Sairenji, T. and Humphries, R.E. (1983) Functional association of class II antigens with cell surface binding of Epstein-Barr virus, J. Immunol. 134, 3776-3780.

98 Ricci, C.M., Lenches, E.M., Eddy, S.R., Shin, S.J., Sheets, R.L. and Strauss, J.H. (1985) Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution, Science 229, 720-723.

99 Richman, D.D., Hostetter, K.Y., Yazaki, P.J. and Clark, S. (1986) Fate of Influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine, Virology 151, 200-210.

100 Rogers, G.N., Paulson, J.C., Daniels, R.S., Skehel, J.J., Wilson, I.A. and Wiley, D.C. (1983) Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity, Nature 301, 76-78.

101 Rossman, M.G., Arnold, E., Erickson, J.W., Frankenberger, E.A., Griffith, J.P., Hecht, H.-J., Johnson, J.E., Kamer, G., Luo, M., Mosser, A.G., Rueckert, R.R., Sherry, D. and Vriend, G. (1985) Structure of a human common cold virus and functional relationship to other picornaviruses, Nature 317, 145-153.

102 Ruoslbah, E. and Pierschbacher, M.D. (1986) Arg-Gly-Asp: a versatile cell recognition signal, Cell 44, 517-518.

103 Rueckert, R.R. (1985) Picornaviruses and their replication. In: B.N. Fields (Ed.), Virology, Raven Press, New York, pp. 705-738.

104 Saima, P.S., Cheong, M.P., Hartley, J.W. and Huebner, R.J. (1967) A viral interference test for mouse leukemia viruses, J. Virol. 33, 180-184.

105 Sattentau, Q., Dalgleish, A.G., Weiss, R.A. and Beverley, P. (1986) Epitopes of the CD4 antigen and HIV infection, Science 234, 1120-1127.

106 Schlegel, R., Tralka, T.S., Willingham, M.C. and Pastan, I. (1983) Inhibition of VSV binding and infectivity by phosphorylserine. Is phosphorylserine a VSV binding site? Cell 32, 639-646.

107 Schmitz, T.J., Weiss, R.A., Juricek, D.K. and Ruddle, F.H. (1980) Use of Vesicular Stomatitis Virus pseudotypes to map virus receptor genes: Assignment of the RD114 virus receptor gene to human chromosome 19, J. Virol. 35, 575-580.

108 Schmitz, T.J., Weiss, R.A. and Zavada, J. (1977) Pseudotypes of vesicular stomatitis virus with the envelope properties of mammalian and primate retroviruses, J. Virol. 23, 449-454.

109 Sharpe, A.H. and Fields, B.N. (1985) Pathogenesis of viral infections; basic concepts emerging from the reovirus model, New Engl. J. Med. 312, 486-497.

110 Silverman, L.J. and Griffin, B.E. (1987) Myristic acid is coupled to a structural protein of polyoma virus mRNA, Nature 326, 619-622.

111 Silverman, L.J., Nibert, M., Furlong, D. and Fields, B.N. (1987) Intracellular digestion of reovirus particles requires a low pH and is an essential step in the viral infectious cycle, J. Virol. 61, 2351-2361.

112 Suzuki, Y., Matsunaga, M. and Matsumoto, M. (1985) N-acetylneuraminylactosylceramide, GM3-
NeuAc, a new influenza A virus receptor which mediates the adsorption-fusion process of viral infection. Binding specificity of influenza virus A/Aichi/2/68 (H3N2) to membrane-associated GM3 with different molecular species of sialic acid, J. Biol. Chem. 260, 1362–1365.

118 Svensson, U., Persson, R. and Everit, E. (1981) Virus-receptor interaction in the adenovirus system. I. Identification of virion attachment proteins of the HeLa cell plasma membrane, J. Virol. 38, 78–81.

119 Talbot, P.J. and Vance, D.E. (1982) Biochemical studies on the entry of Sindbis virus into BHK-21 cells and the effect of NH4Cl, Virology 118, 451–455.

120 Tanner, J., Weis, J., Fearon, D., Whang, Y. and Kieff, E. (1987) Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capped and endocytosis, Cell 50, 203–213.

121 Tedder, T.F., Goldmacher, V.S., Lambert, J.M. and Schlossman, S.F. (1986) Epstein-Barr virus binding induces internalisation of the C3d receptor: A novel immunotoxin delivery system, J. Immunol. 137, 1387–1391.

122 Thung and Gerber (1984) Polyalbumin receptors: Their role in the attachment of Hepatitis B virus to Hepatocytes, Seminars in Liver Disease. 4, 69–75.

123 Tignor, G.H., Smith, A.L. and Shope, R.E. (1984) In: A.L. Notkins and M.B.A. Oldstone (Eds.), Concepts in viral pathogenesis, Springer-Verlag, Berlin, pp. 109–116.

124 Tomassini, J.E. and Colomno, R.J. (1986) Isolation of a receptor protein involved in attachment of human rhinoviruses, J. Virol. 58, 290–295.

125 Väänänen, P. and Kääriäinen, L. (1979) Haemolysis by two alphaviruses: Semliki Forest and Sindbis virus, J. Gen. Virol. 43, 593–601.

126 Webster, R.G. and Askonas, B.A. (1980) Cross-protection and cross-reactive cytotoxic T-cells induced by influenza virus vaccines in mice, Eur. J. Immunol. 10, 396–401.

127 Weiner, H.L., Drayna, D., Averill, D.R., Jr. and Fields, B.N. (1977) Molecular basis of reovirus virulence: Role of the S1 gene. Proc. Natl. Acad. Sci. USA 74, 5744–5755.

128 Weis, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J. and Wiley, D.C. (1988) Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid, Nature 333, 426–431.

129 Weiss, R.A. (1981) Retrovirus receptors and their genetics. In: K. Lonberg-Holm and L. Phillips (Eds.), Virus Receptors, Part 2. Animal Viruses, Receptors and Recognition Series B. Vol. 8, Chapman and Hall, London, pp. 185–202.

130 Weiss, R.A. and Benett, P.L.P. (1980) Assembly of membrane glycoproteins studied by pheno-typic mixing between mutants of vesicular stomatitis virus and retroviruses, Virology 100, 252–274.

131 Weiss, R.A., Boettiger, D. and Love, D.N. (1974) Phenotypic mixing between vesicular stomatitis virus and avian RNA tumor viruses, CSHSQB 39, 913–918.

132 Weiss, R.A. (1984) Tissue-specific transformation by human T-cell leukaemia viruses, Nature 310, 273–274.

133 Weiss, R.A., Clapham, P., Nagy, K. and Hoshino, H. (1985) Envelope properties of human T-cell leukaemia viruses, Curr. Top. Microbiol. Immunol. 115, 235–245.

134 White, J., Kielian, M. and Helenius, A. (1983) Membrane fusion proteins of enveloped viruses, Q. Rev. Biophys. 16, 151–195.

135 Wilson, I.A., Skehel, J.J. and Wiley, D.C. (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 Å resolution, Nature 289, 366–373.

136 Wolf, J.L., Kauffman, R.S., Finberg, R., Dambrasukas, R., Fields, B.N. and Trier, J.S. (1983) Determinants of Reovirus interaction with the enteric M cells and adsorptive cells of murine intestine, Gastroenterology 85, 291–300.

137 WuDunn, D. and Spear, P.G. (1987) Cell surface receptor for Herpes Simplex virus is heparan sulphate proteoglycan, 12th International Herpes virus workshop, Abstr. p. 107.

138 Young, L.S., Sixbey, J.W., Clark, D. and Rickinson, A.B. (1986) Epstein-Barr virus receptors on human pharyngeal epithelia, Lancet i, 240–242.

139 Yoshimura, A. and Ohnishi, S.-I. (1984) Uncoating of Influenza virus in endosomes, J. Virol. 51, 497–504.

140 Zagury et al. (1988) A group-specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS, Nature 332, 728–731.